argenx SE Website

argenx SE

NasdaqGS-ARGX

Company Overview

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

  • Name

    argenx SE

  • CEO

    Timothy Van Hauwermeiren

  • Website

    argenx.com

  • Sector

    Biotechnology

  • Year Founded

    2008

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Novel FcRn inhibitor Vyvgart is a pipeline in a product, currently approved in myasthenia gravis and CIDP in the US, but it's being evaluated in multiple additional indications.

  • Vyvgart’s approval in myasthenia gravis made it the first-to-market FcRn-targeting drug, putting Argenx in a strong position to entrench itself in the market before competitors arrive.

  • With exclusive access to Halozyme's subcutaneous drug delivery technology, Argenx can improve the convenience of Vyvgart and potentially differentiate its drug from future competition.

Bears Say

  • Vyvgart’s initial average price in myasthenia gravis of $225,000 per year per patient in the US could fall over time, as international launches progress and as competitors reach the market.

  • While Vyvgart showed impressive efficacy in two indications, other potential indications are less clearly caused by autoantibodies, and pivotal data has been mixed in ITP and dermatology indications.

  • Firms like Johnson & Johnson, UCB, and Immunovant are also aggressively pursuing FcRn inhibitors that could prove just as effective as, or more effective than, Vyvgart.

Source: Morningstar Analysis - Nov 03, 2025

What's happening

Nov 4, 2025 - Dec 4, 2025

Argenx SE Surges Amid Positive Developments and Analyst Upgrades

  • argenx received Health Canada approval for VYVGART SC, enhancing its product offerings.
  • Analysts remain bullish on ARGX despite concerns about profit margins and competition.
  • The company outperformed the S&P 500 by 11.1% over the past month.

Over the past month, argenx SE (ARGX) experienced a notable increase of 10.8%, significantly outperforming the S&P 500, which declined by 0.3%. This performance reflects strong investor sentiment driven by positive developments surrounding the company’s product pipeline and market positioning. A key opinion leader expressed optimism regarding therapeutic options for Sjögren's syndrome, placing argenx alongside major players like Johnson & Johnson and Amgen, which likely bolstered investor confidence in ARGX's future prospects.

On November 6, argenx secured Health Canada approval for VYVGART SC as a monotherapy for chronic inflammatory demyelinating polyneuropathy (CIDP). This milestone was based on promising clinical study results showing substantial patient improvement rates. Following this announcement, analysts reacted positively; Piper Sandler raised their price target to $930 while maintaining an Overweight rating on the stock. Similarly, Deutsche Bank increased its target to EUR675 with a Hold rating.

Despite some bearish sentiments earlier in November due to concerns about declining profit margins amid rising competition and pricing pressures, overall analyst outlook remained optimistic throughout this period. Multiple firms raised their price targets while maintaining favorable ratings on ARGX shares; notably Oppenheimer adjusted its price target from $778 to $1,040 while keeping an Outperform rating—indicating confidence in long-term growth potential.

The company's financials reflect strength with impressive earnings growth over recent years and projections suggesting continued revenue increases supported by strategic collaborations and expanding pipelines despite acknowledged execution risks as critical factors moving forward. Overall trends indicate that investors maintain optimism regarding argenx SE's trajectory within the biotechnology sector.

In summary of relative performance metrics during this one-month period marked by significant developments including regulatory approvals and analyst upgrades: argenx SE outperformed both broader market trends where S&P declined slightly during this timeframe; additionally, argenx SE outperformed the Health Care (XLV) sector by 3.4%.

NasdaqGS:ARGX